183 related articles for article (PubMed ID: 34599642)
21. The importance of BRAF-V600E mutation to ameloblastoma metabolism.
Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP
J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334
[TBL] [Abstract][Full Text] [Related]
22. Perioperative BRAF inhibitors in locally advanced stage III melanoma.
Zippel D; Markel G; Shapira-Frommer R; Ben-Betzalel G; Goitein D; Ben-Ami E; Nissan A; Schachter J; Schneebaum S
J Surg Oncol; 2017 Dec; 116(7):856-861. PubMed ID: 28650570
[TBL] [Abstract][Full Text] [Related]
23. BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital.
Kelppe J; Thorén H; Ristimäki A; Haglund C; Sorsa T; Hagström J
Oral Dis; 2019 May; 25(4):1169-1174. PubMed ID: 30811720
[TBL] [Abstract][Full Text] [Related]
24. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.
Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF
Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review.
Yoithapprabhunath TR; Srichinthu KK; Gupta D; Singh D; Pasupuleti S; Nirmal RM
Indian J Dent Res; 2022; 33(3):323-331. PubMed ID: 36656197
[TBL] [Abstract][Full Text] [Related]
26. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
[TBL] [Abstract][Full Text] [Related]
27. Is Conservative Surgical Treatment Sufficient to Treat Unicystic Mural Ameloblastoma in Infant?
Acar AH; Yolcu Ü; Erdem NF; Asutay F
J Craniofac Surg; 2015 Jun; 26(4):e297-9. PubMed ID: 26080238
[TBL] [Abstract][Full Text] [Related]
28. It was not possible to detect BRAF V600E mutation in circulating cell-free DNA from patients with ameloblastoma: A diagnostic accuracy study.
Martins-de-Barros AV; da Costa Araújo FA; Barros AMI; Dos Santos EGF; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; Neves RFSN; de Hollanda Valente RO; de Oliveira E Silva ED; de Vasconcelos Carvalho M
J Oral Pathol Med; 2024 Apr; 53(4):258-265. PubMed ID: 38494749
[TBL] [Abstract][Full Text] [Related]
29. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: Implications to the clinical practice.
Sant'Ana MSP; Dos Santos Costa SF; da Silva MP; Martins-Chaves RR; Pereira TDSF; de Oliveira EM; Martínez Pedraza R; de Castro WH; Gomes CC; Gomez RS; Fonseca FP
J Oral Pathol Med; 2021 May; 50(5):478-484. PubMed ID: 33377543
[TBL] [Abstract][Full Text] [Related]
30. High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
Derakhshan S; Aminishakib P; Karimi A; Saffar H; Abdollahi A; Mohammadpour H; Kharazi Fard MJ; Memarha A
Med Oral Patol Oral Cir Bucal; 2020 Jul; 25(4):e502-e507. PubMed ID: 32388526
[TBL] [Abstract][Full Text] [Related]
31. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
32. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
[TBL] [Abstract][Full Text] [Related]
33. Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors.
Yi JR; Zhong NN; Lin H; Liu XH; Yang Y; Liu B; Man QW
J Stomatol Oral Maxillofac Surg; 2024 Jun; 125(3S):101846. PubMed ID: 38556167
[TBL] [Abstract][Full Text] [Related]
34. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
35. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
Yan XC; Sun LS; Dong ZW; You Z; Dong Q
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
[TBL] [Abstract][Full Text] [Related]
36. Whole exome sequencing and system biology analysis support the "two-hit" mechanism in the onset of Ameloblastoma.
Shi Y; Li M; Yu Y; Zhou Y; Wang S
Med Oral Patol Oral Cir Bucal; 2021 Jul; 26(4):e510-e517. PubMed ID: 33395399
[TBL] [Abstract][Full Text] [Related]
37. Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report.
Noda Y; Sawada S; Sakagami T; Kojima Y; Higasa K; Tsuta K
Head Neck Pathol; 2023 Sep; 17(3):788-792. PubMed ID: 37093491
[TBL] [Abstract][Full Text] [Related]
38. BRAF V600E mutational status in pediatric thyroid cancer.
Henke LE; Perkins SM; Pfeifer JD; Ma C; Chen Y; DeWees T; Grigsby PW
Pediatr Blood Cancer; 2014 Jul; 61(7):1168-72. PubMed ID: 24677749
[TBL] [Abstract][Full Text] [Related]
39. Progress towards personalized medicine for ameloblastoma.
Gomes CC; Diniz MG; Gomez RS
J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
[TBL] [Abstract][Full Text] [Related]
40. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
